Aptevo Therapeutics (NASDAQ:APVO) Share Price Passes Below Fifty Day Moving Average – Here’s Why

Aptevo Therapeutics Inc. (NASDAQ:APVO) passed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $3.22 and traded as low as $1.73. Aptevo Therapeutics shares last traded at $1.84, with a volume of 423,830 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings raised Aptevo Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, September 10th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Aptevo Therapeutics Price Performance

The stock has a market cap of $3.33 million, a price-to-earnings ratio of -0.04 and a beta of 1.60. The firm has a fifty day moving average of $3.18 and a 200 day moving average of $4.25.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($5.31) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.02) by $0.71. Research analysts anticipate that Aptevo Therapeutics Inc. will post -19.3 earnings per share for the current fiscal year.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.